pembrolizumab

Mon, 12 Jul 2021 10:45:41 -0400
​For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)